Articles

Children with acute lymphoblastic leukemia (ALL) who have mutations in the CREBBP gene are more likely to relapse according to a team of researchers with St. Jude Children's Research Hospital and the National Cancer Institute. The CREBBP gene produces CREB binding protein, an enzyme involved in cell growth and division. According to the investigators, CREBBP also regulates genes essential to normal blood cell development.

By Christin Melton

TON - Daily

Patients with lung cancer who received daily fish oil supplements experienced greater tumor shrinkage during chemotherapy and longer overall survival (OS) and were less likely to lose weight than patients taking placebo. The study was led by Vera Mazurak, PhD, an expert in nutrition and metabolism with the Department of Agricultural, Food and Nutritional science at the University of Alberta in Canada.

By Christin Melton

TON - Daily

Chemotherapy might contribute to balance problems in postmenopausal women with breast cancer, according to researchers from the Knight Cancer Institute at Oregon Health and Science University. They enrolled 59 breast cancer survivors (average age, 58 years) and compared their incidence of falls with the annual reported rate for historical controls living in a community setting.

By Bonnie Gillis

TON - Daily

ORLANDO, FL— The news was promising regarding several drugs for the treatment of prostate cancer at the recent ASCO Genitourinary Cancers Symposium held February 17-19, 2011 An extension-phase study of degeralix, approved by the FDA in 2008, confirmed the efficacy of this drug versus leuprolide. Other positive studies focused on drugs in various stages of development, including abiraterone, cabozantinib, and MDV3100.

Degarelix (Firmagon, Ferring)

By Christin Melton

TON - Daily

Data published in the Lancet this week support the effectiveness of eribulin mesylate (Halaven)—a microtubule inhibitor—in women with advanced breast cancer that has progressed after several treatments. The FDA approved eribulin in November 2010 for metastatic breast cancer patients treated with at least two chemotherapy regimens (an anthracycline and a taxane). Read More ›

Variation in Prescribing Instructions Confuses Patients on Multi-Drug Regimens

By Kim Melofchik

TON - Daily

Every physician has a preferred way of writing prescription instructions, and pharmacists differ in how they translate those instructions to the pill bottle. A study published in the Annals of Internal Medicine by Wolf and associates found that the lack of a universal medication schedule (UMS) to standardize how prescriptions are written and filled contributes to poor patient adherence and increases safety concerns. Read More ›

Rise in PSA Levels Poor Predictor of Prostate Cancer

By Christin Melton

TON - Daily

A rise in prostate-specific antigen (PSA)—known as PSA velocity—does not predict the likelihood of prostate cancer in asymptomatic men according to a study published in the Journal of the National Cancer Institute. Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) in New York said relying solely on PSA velocity to determine who should undergo biopsy would lead to hundreds of unnecessary biopsies without improving outcomes.

By Christin Melton

TON - Daily

A small Canadian study found that patients who took THC (delta-9-tetrahydrocannabinol), the psychoactive ingredient in marijuana, slept better and derived more enjoyment from eating than patients given a placebo. The University of Alberta investigators, led by associate professor Wendy Wismer, recruited terminal patients with advanced cancer who were randomly assigned to take 2.5 mg of dronabinol (a pill form of THC) or placebo twice a day for 18 days. Read More ›

Intermittent Androgen Suppression Recommended as New Standard in Recurrent Prostate Cancer

By Christin Melton

TON - Daily

Data from a study presented at the 2011 Genitourinary Cancers Symposium supports the growing consensus that intermittent androgen suppression is no less effective than continuous androgen suppression at treating men with prostate cancer that recurs after radiotherapy. Read More ›

Balloon Kyphoplasty Associated with Less Pain and Greater Mobility

By Christin Melton

TON - Daily

In a randomized trial of patients with cancer and vertebral compression fractures (VCFs), balloon kyphoplasty was associated with greater pain relief and better of quality of life than nonsurgical care. According to the authors, patients who received kyphoplasty relied significantly less on pain medication, bed rest, and walking assistance 1 month after the procedure.

Articles

View the Latest Issue of TON

Subscribe Today!

I'd like to receive:

Articles

Page 348 of 376

View the Latest Issue of TON

Subscribe Today!

I'd like to receive: